Navigation Links
BioPrime Array CGH Genomic Labeling System from Invitrogen

ProductsBioPrime Array CGH Genomic Labeling System from Invitrogen
Company Invitrogen
Item BioPrime Array CGH Genomic Labeling System
Price 
Description The BioPrime Plus Array CGH Genomic Labeling Systems are a high-performance labeling kits that enable reproducible labeling of genomic DNA samples for array-based Comparative Genomic Hybridization (CGH). Available in both indirect and direct labeling formats, the BioPrime Plus Array CGH Genomic Labeling Systems provide a flexible solution to your genomic labeling needs.

Using the BioPrime Plus Array CGH Genomic Labeling Systems, you can expect:
High yields of fluorescently labeled genomic DNA • signal-to-noise ratios • detection of gene copy number variations.


These systems combine a highly concentrated exo-Klenow fragment of DNA polymerase I and random primers to effectively label genomic targets for sensitive genomic profiling experiments. Exo-Klenow is a mutant of the large fragment of the DNA polymerase I holoenzyme that has both 5 and 35 exonuclease activity removed. The lack of exonuclease activity makes this enzyme ideal for use in random priming protocols, enabling robust yields and efficient incorporation of Alexa Fluor AHA fluorescent nucleotides. In the BioPrime Plus Array CGH Genomic Labeling Systems, random octamers anneal to template DNA, providing priming sites for the exo- Klenow enzyme. Alexa Fluor AHA modified nucleotides (direct labeling) or amino-allyl modified nucleotides (indirect labeling) are incorporated as the polymerase extends from the priming sites. The labeled samples are then purified to remove contaminants prior to denaturing and hybridization to a microarray (direct labeling systems) or coupled to the Alexa Fluor NHS ester (indirect labeling systems) prior to hybridization.

Contents:
The BioPrime Core Module is found in all standard BioPrime and BioPrime Plus Systems and Modules. It contains exo-Klenow fragment (40 U/ l), 2.5X random primer solution (octamers), control DNA (Salmon Sperm), stop buffer, and distilled water. Store at -20C. The BioPrime Plus Systems and Modules contain the Alexa Fluor modified dNTP mixes or amine modified dNTP mixes and the Alexa Fluor NHS Esters. Store at -20C. The standard BioPrime and BioPrime Plus Array CGH Genomic Labeling Systems also contain purification columns and purification buffers.
Info InvitrogenInvitrogen
Invitrogen Corporation
1600 Faraday Ave.
Carlsbad, CA 92008

Call Invitrogen to buy products (US and Canada only; other locations use numbers below)
USA Canada 1-866-521-4270
Customer Service: 800-955-6288
Tech Support: 800-955-6288 ext. 2
Fax Number: 760-603-7229
Web Site: http://www.invitrogen.com
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. BioPrime Plus Array CGH Indirect Genomic Labeling Module from Invitrogen
2. BioPrime Array CGH Genomic Labeling Module from Invitrogen
3. Rapid-Screen Arrayed cDNA Library Panels Master Plates -Human Placenta from OriGene Technologies
4. Rapid-Screen Arrayed cDNA Library Panels Master Plates -Human Heart from OriGene Technologies
5. Rapid-Screen Arrayed cDNA Library Panels Master Plates -Mouse Testis from OriGene Technologies
6. Rapid-Screen Arrayed cDNA Library Panels Master Plates -Mouse Brain (adult) from OriGene Technologies
7. Rapid-Screen Arrayed cDNA Library Panels Master Plates -Mouse Embryo (12.5 - day) from OriGene Technologies
8. Rapid-Screen Arrayed cDNA Library Panels Master Plates -Mouse Embryo (19 - day) from OriGene Technologies
9. Rapid-Screen Arrayed cDNA Library Panels Master Plates -Mouse Thymus from OriGene Technologies
10. Rapid-Screen Arrayed cDNA Library Panels Master Plates -Rat Brain (adult) from OriGene Technologies
11. eArray from Agilent Technologies
(Date:5/27/2015)... , May 27, 2015   ... medication safety systems and image documentation solutions ... of comprehensive, technologically-advanced automation solutions, is pleased ... integration. The Codonics® Safe Label System® (SLS), ... in conjunction with the Omnicell Anesthesia Workstation, ...
(Date:5/22/2015)... 2015 According to a new ... 3D, Thermal, Emotion, Forensic), by Software (Middleware, Databases), by Hardware ... Consumer and Home) - Global Forecast to 2020", published ... Billion in 2015 to $6.19 Billion by 2020, at ... market data Tables and   43 Figures spread through ...
(Date:5/20/2015)... , May 20, 2015 NXT-ID, Inc. ... that its wholly owned subsidiary, 3D-ID LLC, a company ... Team Battelle for the biometrics technology portion of the ... Contract from the Department of the Army. ... products developed for government, law enforcement and security agencies. ...
Breaking Biology News(10 mins):Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3
... the Gulf of Mexico could soon catch the oil slick ... Keys, scientists are monitoring the situation closely with ESA,s Envisat ... information with Envisat Advanced Synthetic Aperture Radar (ASAR) data of ... direction in which the spill boundaries can drift. ,In these ...
... Arabinoxylan, the major dietary fibre component of wheat ... point of view. New enzymatic technologies were developed in ... The results offer potential for a new soluble fibre ... of cereal fibre, in particular in the prevention of ...
... A wide range of gluten free cereals have been ... of the European Union, and their impact on product ... as high-pressure processing technology have been successfully applied to ... free cereal products. In genetically susceptible individuals, the ...
Cached Biology News:Envisat monitors oil spill proximity to Loop Current 2New and improved gluten-free foods developed for patients with celiac disease 2
(Date:5/30/2015)... RARITAN, N.J. , May 30, 2015 ... single-arm Phase 2 MMY2002 (SIRIUS) trial show treatment ... monoclonal antibody – achieved an overall response rate ... assessed by an independent review committee, in heavily ... consistent among the pre-specified subgroups based on age, ...
(Date:5/29/2015)... Los Gatos, CA (PRWEB) May 29, 2015 ... diagnostics company addressing multi-drug-resistant organisms (MDROs), announced that ... technology for same-shift bacterial detection and susceptibility testing ... asm2015 on May 31, 2015 in ... a new class of molecular diagnostics that can ...
(Date:5/29/2015)... Columbia, Pa. (PRWEB) May 29, 2015 ... Thermal Product Solutions with a request to design ... remove excess moisture from prescription medications being produced ... custom solution that includes a robotic gantry, heat-saving ... positions and dries trays of 3D-printed pills to ...
(Date:5/29/2015)... Results from a Phase III clinical trial examining ... reduce the size of melanoma tumors in patients injected ... of Clinical Oncology. , The global, randomized trial ... melanoma, a potentially fatal form of skin cancer. The ... safety and efficacy of the oncolytic virus immunotherapy compared ...
Breaking Biology Technology:Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 2Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 3Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 4Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 5Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 6Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 7Data Highlighting GeneWEAVE’s Smarticles™ Technology to be Presented at the 115th General Meeting of the American Society for Microbiology (asm2015) 2Data Highlighting GeneWEAVE’s Smarticles™ Technology to be Presented at the 115th General Meeting of the American Society for Microbiology (asm2015) 3New industrial oven with “pill pushing” robotic gantry precisely removes excess moisture from 3D-printed pharmaceuticals 2Study Published in Journal of Clinical Oncology Reports Talimogene Laherparepvec Improvesdurable Responses in Patients with Advanced Melanoma 2